CN112710640A - Method for evaluating interleukin level in serum based on epidermal keratin and fragment content - Google Patents
Method for evaluating interleukin level in serum based on epidermal keratin and fragment content Download PDFInfo
- Publication number
- CN112710640A CN112710640A CN201911021797.2A CN201911021797A CN112710640A CN 112710640 A CN112710640 A CN 112710640A CN 201911021797 A CN201911021797 A CN 201911021797A CN 112710640 A CN112710640 A CN 112710640A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- keratin
- serum
- fragments
- epidermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/645—Specially adapted constructive features of fluorimeters
- G01N21/6456—Spatial resolved fluorescence measurements; Imaging
- G01N21/6458—Fluorescence microscopy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
The invention provides a method for evaluating the level of interleukin in serum based on the content of epidermal keratin and fragments; the method detects the levels of epidermal keratin 1, keratin 10 and fragments thereof by using an optical means, thereby obtaining the evaluation of the levels of interleukins (including interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10) in serum. The invention finds that the sum of the contents of the epidermal keratin 1 and the keratin 10 and the sum of the contents of the fragments thereof are in positive correlation with the level of the interleukins in the serum, so that the levels of the epidermal keratin 1 and the keratin 10 and the fragments thereof can be detected by using optical means such as autofluorescence detection, Raman spectrum detection and the like, thereby obtaining the evaluation of the level of the interleukins in the serum.
Description
Technical Field
The invention relates to a method for evaluating the level of interleukin in serum based on the content of epidermal keratin and fragments.
Background
Interleukin, or interleukin (Interlukin), refers to a lymphokine that interacts with leukocytes or immune cells and is a cytokine of the same genus as blood cell growth factor. The two are mutually coordinated and interacted to jointly complete the functions of hematopoiesis and immunoregulation. Interleukins play an important role in transmitting information, activating and regulating immune cells, mediating the activation, proliferation and differentiation of T and B cells, and in inflammatory responses.
Interleukin 1 β is a pro-inflammatory factor that plays a key role in the immune response of the human body to toxic stimuli both internally and externally to the body. Interleukin 2 plays an important role in T cell proliferation and other key functions. Interleukin 5 stimulates B cells to produce antibodies, which also play an important role in the differentiation and proliferation of eosinophils. Interleukin-6 is a cytokine that plays an important role in the immune response of the human body during the acute phase of the immune response, as well as in the process of hematopoiesis. Interleukin 10 is a cytokine that plays multiple roles in the development of autoimmune diseases and cancer. Interleukin 12(p40) is a cytokine with immune regulation function.
The current main method for detecting the level of the above interleukins in serum is by blood test. This method has the drawback of being invasive and requiring a professional doctor and nurse to perform the operative tests. It is of great value to find a method and technique for non-invasive assessment of these interleukin levels.
Disclosure of Invention
The invention aims to provide a method for evaluating the level of interleukin in serum based on the content of epidermal keratin and fragments; in particular to a method for evaluating the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum based on the content change of epidermal keratin 1, keratin 10 and fragments thereof. The method obtains an assessment of the levels of these interleukins in serum by detecting the levels of epidermal keratin 1 and keratin 10 and fragments thereof using optical means.
The purpose of the invention is realized by the following technical scheme:
in a first aspect, the present invention relates to a non-diagnostic therapeutic method for assessing the level of interleukins in serum based on epidermal keratin and fragment content, said method comprising the steps of:
s1, detecting the content of the epidermal keratin 1, the keratin 10 and the fragments thereof by an optical means;
s2, evaluating the interleukin level in the serum according to the obvious positive correlation between the content of the epidermal keratin 1, the content of the keratin 10 and the fragment thereof and the concentration of the interleukin in the serum.
The method is applied to the non-clinical field, can be used for evaluating the interleukin level in the serum of non-disease people, and can also be used for evaluating healthy or sub-healthy people.
Further, the interleukins include interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10.
Further, in step S1, the optical means includes autofluorescence detection and raman spectroscopy detection.
Further, in step S1, when the autofluorescence detection is adopted, the excitation light is 450-580 nm, and the received light is 500-580 nm.
Further, in step S1, the epidermis refers to the epidermis of all human skin. Preferably the epidermis of the fingers, palms, arms, face; more preferably the epidermis of the finger or arm.
Further, in step S2, when the total content of epidermal keratin 1 and keratin 10 or the total content of fragments of epidermal keratin 1 and keratin 10 is higher, the concentration of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum is determined to be higher; when the total content of epidermal keratin 1 and keratin 10 or the total content of fragments of epidermal keratin 1 and keratin 10 is lower, the concentrations of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum are judged to be lower.
Further, in step S2, the concentration of the interleukin in the serum includes the concentration of one or more of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10 in the serum.
In a second aspect, the invention also relates to a dedicated device for using the aforementioned method. In particular to a special device of a method for evaluating the interleukin level in serum based on the content of epidermal keratin and fragments.
In a third aspect, the invention also relates to a marker for non-invasive assessment of interleukin levels in serum, said marker being epidermal keratin 1 and keratin 10 and fragments thereof.
As an embodiment of the present invention, there is provided the use of epidermal keratin 1 and keratin 10, and fragments thereof, as markers for non-invasive assessment of the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum.
In a fourth aspect, the invention also relates to an evaluation model for evaluating the interleukin in serum based on the content of the epidermal keratin and the fragments, wherein the content of the epidermal keratin 1, the keratin 10 and the fragments thereof has a significant positive correlation with the concentration of the interleukin in the serum.
The above methods for evaluating the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10 in serum and the apparatuses based on these methods have various applications, including noninvasive evaluation of the levels of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10 in serum in various scenes such as homes, communities, and the like.
The above methods of assessing the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum and the instruments and apparatus according to these methods may be of non-medical interest.
Compared with the prior art, the invention has the following beneficial effects:
1) the levels of epidermal keratin 1, keratin 10 and fragments thereof can be detected by optical means such as autofluorescence detection, Raman spectrum detection and the like, so as to obtain the evaluation of the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum;
2) the present inventors have found that keratin 1 and keratin 10 and fragments thereof in the skin can be used as biomarkers; the marker can be applied to the assessment and detection of serum interleukin concentration.
Drawings
FIG. 1 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 1 alpha;
FIG. 2 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 1 β;
FIG. 3 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 2;
FIG. 4 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 5;
FIG. 5 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 6;
FIG. 6 shows a quantitative graph of the correlation between the total content of keratin 1 and keratin 10 and the total content of fragments thereof and the concentration of interleukin 10.
Detailed Description
The present invention will be described in detail with reference to examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that it would be apparent to those skilled in the art that several modifications and improvements can be made without departing from the inventive concept. All falling within the scope of the present invention. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the terms "autofluorescence," "auto-fluorescence," are interchangeable and refer to the phenomenon in which a tissue, cell, or biological substance absorbs energy of excitation light into an excited state after being irradiated with excitation light of an appropriate wavelength, and emits light longer than the wavelength of the excitation light when exiting the excited state, wherein autofluorescence is light longer than the wavelength of the excitation light.
As used herein, the term "excitation light" refers to light capable of exciting a biomolecule to undergo an autofluorescence phenomenon, which should be shorter in wavelength than the autofluorescence.
As used herein, "keratin," "KRT," are interchangeable and are referred to herein specifically as keratin 1 and keratin 10 and fragments thereof. It is intended to include keratins which can be recognized using antibodies to keratin 1 and keratin 10, which are mixtures, and which are the sum of keratin 1 and keratin 10 and fragments thereof.
The term "Interleukin", abbreviated Interleukin, or "Interleukin" in the English language used herein refers to a lymphokine that interacts with leukocytes or immune cells and is a cytokine belonging to the same genus as the blood cell growth factor. The two are mutually coordinated and interacted to jointly complete the functions of hematopoiesis and immunoregulation. Interleukins play an important role in transmitting information, activating and regulating immune cells, mediating T, B cell activation, proliferation and differentiation, and in inflammatory responses.
Example 1: determination that skin fluorescence is primarily from keratin fragments
The skin autofluorescent substance is mainly keratin 1 and keratin 10 and its fragments, NAD, FAD, collagen, melanin, etc. Each fluorescent substance has a characteristic spectrum.
This example evaluates and detects the spectrum of auto-fluorescence of human skin. The peak was found to be between 470nm and 500nm, based on which the autofluorescence of the skin was believed to be from keratin fragments.
Example 2: confirmation of spontaneous fluorescent substance
In vivo experiments
The body surface keratin 1 and keratin 10 and fragments thereof of the subject are imaged using a microscope. The excitation light used is blue light, and the specific wavelength range is between 470 and 500 nm. Collecting the distribution image and content of the keratin fragments on the body surface of the subject.
Example 3: quantitative evaluation and detection of the concentration of individual interleukin subtypes in serum
Male C57 mice were used and were housed in an animal house at 22-24℃ for 12 hours light/dark cycles and were allowed free access to water. Lipopolysaccharide is injected into the abdominal cavity of the mouse, and after 1 day and 3 days, the body surface keratin 1, the keratin 10 and the fragments thereof of the mouse are imaged according to the invention. The excitation wavelength of the confocal laser scanning microscope is 450-500nm, and 488nm is selected in the present embodiment. The receiving wavelength is 500-580nm, and 500-550nm is selected in this embodiment. Quantification of mouse keratin 1 and keratin 10 and fragments thereof was performed using fluorescence intensity. And quantitatively evaluating and detecting a plurality of interleukin subtypes in the serum of the mouse. Correlation analysis of the two results shows that the levels of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum have significant changes with the keratin content (fig. 1, fig. 2, fig. 3, fig. 4, fig. 5 and fig. 6). And the change is positively correlated with the corresponding interleukin concentration.
From the above experiments, it can be concluded that keratin 1 and keratin 10 and fragments thereof in the skin can be used as biomarkers. The marker can be applied to the assessment and detection of serum interleukin concentration.
It will be apparent to those skilled in the art that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Therefore, the detailed description and examples of the invention should not be construed as limiting the scope of the invention. The invention is limited only by the appended claims. All documents cited in this application are incorporated herein by reference in their entirety.
Claims (10)
1. A non-diagnostic therapeutic method for assessing interleukin levels in serum based on epidermal keratin and fragment levels, comprising the steps of:
s1, detecting the content of the epidermal keratin 1, the keratin 10 and the fragments thereof by an optical means;
s2, evaluating the interleukin level in the serum according to the obvious positive correlation between the content of the epidermal keratin 1, the content of the keratin 10 and the fragment thereof and the concentration of the interleukin in the serum.
2. The method of claim 1, wherein the interleukins include interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10.
3. The method for assessing interleukin levels in serum based on epidermal keratin and fragment content of claim 1, wherein the optical means comprises autofluorescence detection and Raman spectroscopy detection in step S1.
4. The method according to claim 3, wherein in step S1, when the autofluorescence assay is used, the excitation light is 450-500nm and the received light is 500-580 nm.
5. The method for estimating interleukin level in serum according to the content of epidermal keratin and fragments of claim 1, wherein the epidermis is the epidermis of all human skin in step S1.
6. The method according to claim 1, wherein in step S2, the concentration of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in the serum is determined to be higher when the total content of epidermal keratin 1 and keratin 10 or the total content of epidermal keratin 1 and keratin 10 is higher; when the total content of epidermal keratin 1 and keratin 10 or the total content of fragments of epidermal keratin 1 and keratin 10 is lower, the concentrations of interleukin 1 alpha, interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6 and interleukin 10 in serum are judged to be lower.
7. The method of claim 1, wherein in step S2, the concentration of the interleukin in the serum comprises the concentration of one or more combinations of interleukin 1 α, interleukin 1 β, interleukin 2, interleukin 5, interleukin 6, and interleukin 10 in the serum.
8. A special device for using the method for evaluating the interleukin level in serum based on the content of epidermal keratin and fragments as claimed in any one of claims 1 to 7.
9. A marker for non-invasively assessing interleukin levels in serum, wherein said marker is epidermal keratin 1 and keratin 10 and fragments thereof.
10. An assessment model for assessing interleukin in serum based on the content of epidermal keratin and fragments is characterized in that the content of epidermal keratin 1, keratin 10 and fragments thereof has a significant positive correlation with the concentration of interleukin in serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021797.2A CN112710640A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating interleukin level in serum based on epidermal keratin and fragment content |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911021797.2A CN112710640A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating interleukin level in serum based on epidermal keratin and fragment content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112710640A true CN112710640A (en) | 2021-04-27 |
Family
ID=75541424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911021797.2A Pending CN112710640A (en) | 2019-10-25 | 2019-10-25 | Method for evaluating interleukin level in serum based on epidermal keratin and fragment content |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112710640A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102576011A (en) * | 2009-08-07 | 2012-07-11 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN106841131A (en) * | 2016-12-29 | 2017-06-13 | 上海交通大学 | A kind of detection method of biomarker based on keratin autofluorescence as predicted detection tumour and its application |
| CN110161251A (en) * | 2018-02-12 | 2019-08-23 | 上海交通大学 | The application of keratin protein fraction and keratin level as biomarker in the product that preparation is used for diagnosing outside based on nail |
| CN110320184A (en) * | 2018-03-28 | 2019-10-11 | 上海交通大学 | The method and its application of Parkinson's disease are judged based on the detection to skin and nail keratin |
-
2019
- 2019-10-25 CN CN201911021797.2A patent/CN112710640A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102576011A (en) * | 2009-08-07 | 2012-07-11 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN106841131A (en) * | 2016-12-29 | 2017-06-13 | 上海交通大学 | A kind of detection method of biomarker based on keratin autofluorescence as predicted detection tumour and its application |
| CN110161251A (en) * | 2018-02-12 | 2019-08-23 | 上海交通大学 | The application of keratin protein fraction and keratin level as biomarker in the product that preparation is used for diagnosing outside based on nail |
| CN110320184A (en) * | 2018-03-28 | 2019-10-11 | 上海交通大学 | The method and its application of Parkinson's disease are judged based on the detection to skin and nail keratin |
Non-Patent Citations (2)
| Title |
|---|
| MINGCHAO ZHANG,ET AL: "Keratin-Based Epidermal Green Autofluoresce", 《BIORXIV》 * |
| 汪丽蕙等主编: "《今日内科 血液疾病 内分泌疾病分册》", 30 November 1991 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1806093A3 (en) | Classification system for sex determination and tissue characterization | |
| JP3151669B2 (en) | Apparatus for measuring pH of target, method of using the apparatus and use thereof | |
| CN1636506A (en) | Method of assessing skin and overall health of an individual | |
| Samborski et al. | Assessment of skin autofluorescence as a marker of advanced glycation end product accumulation in type 1 diabetes | |
| Karim et al. | Discordance between histologic and visual assessment of tissue viability in excised burn wound tissue | |
| Özsoylu et al. | (Bio-) Sensors for skin grafts and skin flaps monitoring | |
| CN110320184A (en) | The method and its application of Parkinson's disease are judged based on the detection to skin and nail keratin | |
| CN101529228B (en) | Device and method for examining and evaluating a biologically active and/or activatable substance | |
| Greabu et al. | Salivary cortisol-marker of stress response to different dental treatment | |
| CN112710640A (en) | Method for evaluating interleukin level in serum based on epidermal keratin and fragment content | |
| JP4469762B2 (en) | Sensitive skin evaluation method and evaluation kit | |
| CN110763844A (en) | Method for detecting cardiovascular and cerebrovascular disease onset risk product based on nail keratin fragments and keratin content and distribution and application thereof | |
| CN112704492A (en) | Method for evaluating levels of several interleukins in serum based on skin autofluorescence | |
| CN106264469A (en) | The detection method of the biomarker damaged as predicted detection ultraviolet light based on Epidermal Keratin and associated protein thereof and application thereof | |
| CN112710639A (en) | Method for evaluating chemotactic/growth factor level in serum based on epidermal keratin | |
| TW512058B (en) | Spectral analysis system for burning and scalding injuries and device used in the system | |
| CN110881952A (en) | Method for detecting human body clogging product based on human body skin autofluorescence intensity and spatial distribution and application thereof | |
| Shin et al. | Lack of differentiation of allergic and irritant reactions by skin autofluorescence. | |
| CN110161251A (en) | The application of keratin protein fraction and keratin level as biomarker in the product that preparation is used for diagnosing outside based on nail | |
| CN110623633A (en) | Method for detecting human tissue inflammation based on skin autofluorescence and application thereof | |
| Cummins et al. | Raman spectroscopy of fingernails: A novel tool for evaluation of bone quality? | |
| CN112704472A (en) | Method for evaluating chemotactic/growth factor level in serum based on skin autofluorescence | |
| RU2190350C2 (en) | Method for noninvasive express- diagnostics | |
| Jayabal | Identifying early changes in skin integrity using biomarkers | |
| CN110887786A (en) | Method for detecting Alzheimer disease occurrence and severity products based on skin keratin fragments and keratin content and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210427 |
|
| RJ01 | Rejection of invention patent application after publication |